Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Nov 18, 2023 10:06am
Trevor ...
Which one of you is Trevor ?
(560)
•••
TrevorAbes
X
View Profile
View Bullboard History
Post by
TrevorAbes
on Nov 17, 2023 5:25pm
Three of the best penny stocks with competitive advantages
https://stockhouse.com/news/newswire/2023/11/17/three-best-penny-stocks-with-competitive-advantages
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 16, 2023 11:53am
It is possible
that P2 will start 2nd week of january. do not get caught with your pants down trying to get in at a better price . lol In light of the strong safety and PK data from otenaproxesul’s recent
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 16, 2023 9:13am
I wonder
how much we will get bought out for after a succesful P2, there will be a bidding war for ate tylenol, bayer whoever it is will be the first to have a safe non-addictve pain drug on the market
...more
(62)
•••
WalkOverTheStrt
X
View Profile
View Bullboard History
Comment by
WalkOverTheStrt
on Nov 16, 2023 9:02am
RE:comgrats
Have any insiders sold in the past month?
(62)
•••
WalkOverTheStrt
X
View Profile
View Bullboard History
Comment by
WalkOverTheStrt
on Nov 16, 2023 9:00am
RE:RE:News Release
Marcket cap of $90B and ~$350 a share... I think the attempt is to show potential of Antibe if they finally are sucessful and reach the finish line. I'd expect Antibe to hit the editorials/news
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 16, 2023 8:53am
Hey Harper
watch the dan legault video posted below then you will understand
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 16, 2023 8:51am
Dan Legault (latest on otena)
https://cdn.jwplayer.com/previews/1QMsVHS3
(55)
•••
Harper75
X
View Profile
View Bullboard History
Comment by
Harper75
on Nov 16, 2023 8:48am
RE:News Release
I received this email as well but I found it very odd Investor Relations would send out an article that is highlighting another Pharm's progress on their non-opioid pain pill even if it highlights
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 16, 2023 8:40am
News Release
ANTIBE THERAPEUTICS INC. 15 Prince Arthur Ave
...more
(5)
•••
Mmmtroll
X
View Profile
View Bullboard History
Comment by
Mmmtroll
on Nov 15, 2023 12:33pm
RE: bought back in this morning
zero
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 15, 2023 10:26am
also
it would be in the best interest of nuance pharma to to wait and see the P2 results, could be the arbitration decision is to kick the can down the road, should P2 results be possitive i think a deal
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 15, 2023 9:51am
bought back in this morning
after doing some research. How much money can I get back through arbitration? Through the IIROC Arbitration Program, arbitrators can award up to $500,000, but no more. And under IIROC
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 15, 2023 9:48am
2 new target prices
Antibe Therapeutics (ATBPF) In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Antibe Therapeutics, with a price target of C$2.00. The
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Nov 14, 2023 1:35pm
Just for fun
lets do some quick math. as of september/30 end of Q2 antibe has 27.9M nuance likely to win arbitration 20M aproximatley 2 years of interest (ball park figure @4%) = 1.632M 27.9M - 20M - 1.632M
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >